We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Anavex Life Sciences Corp (AVXL) Com Stk USD0.001

Sell:$10.46 Buy:$10.47 Change: $0.18 (1.71%)
NASDAQ:0.23%
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$10.46
Buy:$10.47
Change: $0.18 (1.71%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$10.46
Buy:$10.47
Change: $0.18 (1.71%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.

Contact details

Address:
630 5Th Avenue, 20Th Floor
NEW YORK
10111
United States
Telephone:
+1 (800) 6893939
Website:
https://www.anavex.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AVXL
ISIN:
US0327973006
Market cap:
$894.80 million
Shares in issue:
84.82 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Christopher Missling
    Chairman of the Board, President, Chief Executive Officer, Company Secretary
  • Sandra Boenisch
    Principal Financial Officer, Treasurer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.